In 2024, Nathan J. Dowden earned $709.81K in total compensation at Entrada Therapeutics, including $480.00K salary and $216.01K bonus. Most recently sold 1,694 shares in Sep 2024. Currently holds stock worth $1.85M. 1+ years at the helm of Entrada Therapeutics.
Compensation History
Annual executive compensation data for Nathan J. Dowden, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$709.81K
Salary
$480.00K
Bonus
$216.01K
Other
$13.80K
Salary
$480.00KBoard Justification
The goal was to ensure that the compensation we offer to our executive officers, individually as well as in the aggregate, is competitive and aligned with our business and executive talent requirements.
Bonus
$216.01KBoard Justification
During 2024, each of Mr. Doshi, Dr. Sethuraman and Mr. Dowden were entitled to receive a target bonus of 55%, 45% and 45% of their base salary, respectively. The bonus was calculated on a pro-rata basis accordingly. Based on our achievement of the applicable performance goals for 2024 at 100%, each named executive officer earned the amounts set forth in the “2024 Summary Compensation Table” above.
Other Compensation
$13.80KBoard Justification
The amount reported represents the employer matching contribution to the executive’s 401(k) plan contributions during the relevant year.
Restricted Stock
Board Justification
N/A
Performance Metrics
achievement of certain Company performance metrics
Nathan J. Dowden
CEO of Entrada Therapeutics
Education
B.S. in Finance from University of Connecticut, MBA from University of Chicago Booth School of Business
Sector of Economy
Healthcare
Born
January 1, 1983 - 42 years ago
CEO of Entrada Therapeutics for
1 year 11 months (Jan 2024 - Present)
Previous Experience
Chief Operating Officer at Entrada Therapeutics, Senior VP at Rubius Therapeutics
Other Entrada Therapeutics CEOs
Holdings
Track Nathan J. Dowden's stock holdings and portfolio value over time.
Total Stock Sold
$1.52M
$1.52M
92,230 TRDA shares
What if they kept their stock?
If Nathan J. Dowden didn't sell their stock, today they would have:
Extra TRDA92,230 shares worth $951.81K.
This is -37.37% and $567.91K less than what they got when they sold the stock.
Insider Trading
Nathan J. Dowden's recent stock transactions, purchases, and sales filed with the SEC.
$27.10K
TRDA at $16.00/share
Sep 26, 2024
Sale
$69.70K
TRDA at $15.13/share
Sep 6, 2024
Sale
$446.52K
TRDA at $16.48/share
Aug 16, 2024
Sale
$22.50K
TRDA at $12.32/share
Mar 6, 2024
Sale
93,100 shares
TRDA
Mar 1, 2024
Received
$13.33K
TRDA at $13.72/share
Sep 1, 2023
Sale
14,200 shares
TRDA
Sep 1, 2023
Received
$127.92K
TRDA at $18.02/share
Jul 10, 2023
Sale
$247.37K
TRDA at $15.48/share
Jun 20, 2023
Sale
14,200 shares
TRDA
Mar 1, 2023
Received
Rivals
Compare Nathan J. Dowden with competitor CEOs and industry peers.